ACEPHEN (acetaminophen) by Gland Pharma is 12. Approved for mild to moderate pain in adult, older () management of moderate to severe pain with adjunctive opioid analgesics in adult, older () reduction of fever in adult. First approved in 1978.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ACEPHEN is a rectal suppository formulation of acetaminophen, a well-established analgesic and antipyretic agent. It is indicated for mild to moderate pain, moderate to severe pain as an opioid adjunct, and fever reduction in adults and older patients. The mechanism involves primarily central analgesic and antipyretic actions, though the precise pathway remains incompletely characterized.
As a mature, LOE-approaching product with limited patent protection, the ACEPHEN brand team faces resource constraints and declining headcount, with emphasis shifting toward operational efficiency and supply chain management rather than growth initiatives.
12.1 Mechanism of Action The precise mechanism of the analgesic and antipyretic properties of acetaminophen is not established but is thought to primarily involve central actions. 12.2 Pharmacodynamics Acetaminophen has been shown to have analgesic and antipyretic activities in animal and human…
Worked on ACEPHEN at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients
A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic Pain
A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ACEPHEN offers limited career growth potential given its LOE-approaching status and mature market position; roles focus on operational efficiency, generic defense, and supply chain optimization rather than innovation or commercial expansion. Career progression on this product is constrained, making it more suitable for specialists seeking stable, operational roles or a stepping stone to higher-growth portfolio assets.